Last reviewed · How we verify
Placebo to sugammadex
Placebo to sugammadex is a Selective relaxant binding agent Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery.
Sugammadex is a selective relaxant binding agent that encapsulates rocuronium and other neuromuscular blocking agents, rapidly reversing neuromuscular blockade.
Sugammadex is a selective relaxant binding agent that encapsulates rocuronium and other neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery.
At a glance
| Generic name | Placebo to sugammadex |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Selective relaxant binding agent |
| Target | Rocuronium and other steroidal neuromuscular blocking agents |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Sugammadex works by forming a tight 1:1 complex with rocuronium (and other steroidal neuromuscular blockers), effectively removing the active drug from the neuromuscular junction and shifting the equilibrium to favor reversal of blockade. This allows rapid restoration of neuromuscular function without the need for acetylcholinesterase inhibitors. The complex is then renally eliminated.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
Common side effects
- Nausea
- Vomiting
- Headache
- Hypotension
- Tachycardia
Key clinical trials
- Sugammadex as Rescue Therapy (PHASE4)
- The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex (NA)
- The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group (PHASE4)
- Sugammadex vs Placebo to Prevent Residual Neuromuscular Block (PHASE4)
- Redesigned Process in the Operating Room (PHASE2, PHASE3)
- Sugammadex and Decreased Time to Extubation (PHASE4)
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) (PHASE3)
- A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to sugammadex CI brief — competitive landscape report
- Placebo to sugammadex updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to sugammadex
What is Placebo to sugammadex?
How does Placebo to sugammadex work?
What is Placebo to sugammadex used for?
Who makes Placebo to sugammadex?
What drug class is Placebo to sugammadex in?
What development phase is Placebo to sugammadex in?
What are the side effects of Placebo to sugammadex?
What does Placebo to sugammadex target?
Related
- Drug class: All Selective relaxant binding agent drugs
- Target: All drugs targeting Rocuronium and other steroidal neuromuscular blocking agents
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery